Hugo Dugolin Ceccato, Thiago Antunes de Oliveira E Silva, Livia Moreira Genaro, Julian Furtado Silva, William Moraes de Souza, Priscilla de Sene Portel Oliveira, Anibal Tavares de Azevedo, Maria de Lourdes Setsuko Ayrizono, Raquel Franco Leal
{"title":"人工智能用于炎症性肠病的精准医疗:系统综述。","authors":"Hugo Dugolin Ceccato, Thiago Antunes de Oliveira E Silva, Livia Moreira Genaro, Julian Furtado Silva, William Moraes de Souza, Priscilla de Sene Portel Oliveira, Anibal Tavares de Azevedo, Maria de Lourdes Setsuko Ayrizono, Raquel Franco Leal","doi":"10.62347/XILL3707","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, presents significant clinical challenges due to its heterogeneous nature and complex etiology. Recent advancements in biomedical research have enhanced our understanding of IBD's genetic, microbial, and biochemical aspects. However, persistent issues in clinical management, including treatment non-response, surgical interventions, and diagnostic uncertainties, underscore the need for more targeted approaches. This review examines the convergence of artificial intelligence (AI) and precision medicine (PM) in IBD management. By leveraging AI's capacity to analyze complex, multi-dimensional datasets, this emerging field offers promising applications in improving diagnostic accuracy, predicting treatment responses, and forecasting disease progression, potentially transforming IBD patient care.</p><p><strong>Method: </strong>The systematic review (SR) was conducted by searching the following databases: PubMed, PubMed PMC, BVS, Scopus, Web of Science, Embase, Cochrane, and ProQuest up to February 2024. Studies that employed AI in IBD applied to precision medicine were included.</p><p><strong>Results: </strong>139 studies on applying AI in precision medicine for IBD were identified. Most studies (>70%) were published after 2020, indicating a recent surge in interest. The AI applications primarily focused on diagnosis, treatment response prediction, and prognosis. Machine learning algorithms were predominantly used, particularly random forest, logistic regression, and support vector machines. Omics data were frequently employed as predictors, especially transcriptomics and microbiome analyses. Studies demonstrated good predictive performance across all three areas, with median AUC values ranging from 0.85 to 0.90.</p><p><strong>Conclusion: </strong>AI applications in IBD show promising potential to enhance clinical practice, particularly in disease prognosis and predicting treatment response. However, clinical implementation requires further validation through prospective studies. Future research should focus on standardizing protocols, defining clinically significant outcomes, and evaluating the efficacy of these tools.</p>","PeriodicalId":7731,"journal":{"name":"American journal of translational research","volume":"17 1","pages":"28-46"},"PeriodicalIF":1.6000,"publicationDate":"2025-01-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826164/pdf/","citationCount":"0","resultStr":"{\"title\":\"Artificial intelligence use for precision medicine in inflammatory bowel disease: a systematic review.\",\"authors\":\"Hugo Dugolin Ceccato, Thiago Antunes de Oliveira E Silva, Livia Moreira Genaro, Julian Furtado Silva, William Moraes de Souza, Priscilla de Sene Portel Oliveira, Anibal Tavares de Azevedo, Maria de Lourdes Setsuko Ayrizono, Raquel Franco Leal\",\"doi\":\"10.62347/XILL3707\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, presents significant clinical challenges due to its heterogeneous nature and complex etiology. Recent advancements in biomedical research have enhanced our understanding of IBD's genetic, microbial, and biochemical aspects. However, persistent issues in clinical management, including treatment non-response, surgical interventions, and diagnostic uncertainties, underscore the need for more targeted approaches. This review examines the convergence of artificial intelligence (AI) and precision medicine (PM) in IBD management. By leveraging AI's capacity to analyze complex, multi-dimensional datasets, this emerging field offers promising applications in improving diagnostic accuracy, predicting treatment responses, and forecasting disease progression, potentially transforming IBD patient care.</p><p><strong>Method: </strong>The systematic review (SR) was conducted by searching the following databases: PubMed, PubMed PMC, BVS, Scopus, Web of Science, Embase, Cochrane, and ProQuest up to February 2024. Studies that employed AI in IBD applied to precision medicine were included.</p><p><strong>Results: </strong>139 studies on applying AI in precision medicine for IBD were identified. Most studies (>70%) were published after 2020, indicating a recent surge in interest. The AI applications primarily focused on diagnosis, treatment response prediction, and prognosis. Machine learning algorithms were predominantly used, particularly random forest, logistic regression, and support vector machines. Omics data were frequently employed as predictors, especially transcriptomics and microbiome analyses. Studies demonstrated good predictive performance across all three areas, with median AUC values ranging from 0.85 to 0.90.</p><p><strong>Conclusion: </strong>AI applications in IBD show promising potential to enhance clinical practice, particularly in disease prognosis and predicting treatment response. However, clinical implementation requires further validation through prospective studies. Future research should focus on standardizing protocols, defining clinically significant outcomes, and evaluating the efficacy of these tools.</p>\",\"PeriodicalId\":7731,\"journal\":{\"name\":\"American journal of translational research\",\"volume\":\"17 1\",\"pages\":\"28-46\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2025-01-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11826164/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"American journal of translational research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.62347/XILL3707\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of translational research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/XILL3707","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
炎症性肠病(IBD),包括克罗恩病和溃疡性结肠炎,由于其异质性和复杂的病因,提出了重大的临床挑战。生物医学研究的最新进展增强了我们对IBD的遗传、微生物和生化方面的理解。然而,临床管理中持续存在的问题,包括治疗无反应,手术干预和诊断不确定性,强调需要更有针对性的方法。本文综述了人工智能(AI)和精准医学(PM)在IBD管理中的融合。通过利用人工智能分析复杂、多维数据集的能力,这一新兴领域在提高诊断准确性、预测治疗反应和预测疾病进展方面提供了有前途的应用,可能会改变IBD患者的护理。方法:检索截至2024年2月的PubMed、PubMed PMC、BVS、Scopus、Web of Science、Embase、Cochrane、ProQuest等数据库进行系统评价(SR)。纳入人工智能在IBD中应用于精准医疗的研究。结果:共发现139项AI应用于IBD精准医疗的研究。大多数研究(约70%)发表于2020年之后,这表明最近人们对这一领域的兴趣激增。人工智能的应用主要集中在诊断、治疗反应预测和预后方面。主要使用机器学习算法,特别是随机森林,逻辑回归和支持向量机。组学数据经常被用作预测指标,尤其是转录组学和微生物组学分析。研究表明,这三个领域的预测性能都很好,平均AUC值在0.85到0.90之间。结论:人工智能在IBD中的应用具有增强临床实践的潜力,特别是在疾病预后和预测治疗反应方面。然而,临床应用需要通过前瞻性研究进一步验证。未来的研究应侧重于标准化的方案,确定临床显著的结果,并评估这些工具的有效性。
Artificial intelligence use for precision medicine in inflammatory bowel disease: a systematic review.
Introduction: Inflammatory Bowel Disease (IBD), encompassing Crohn's disease and ulcerative colitis, presents significant clinical challenges due to its heterogeneous nature and complex etiology. Recent advancements in biomedical research have enhanced our understanding of IBD's genetic, microbial, and biochemical aspects. However, persistent issues in clinical management, including treatment non-response, surgical interventions, and diagnostic uncertainties, underscore the need for more targeted approaches. This review examines the convergence of artificial intelligence (AI) and precision medicine (PM) in IBD management. By leveraging AI's capacity to analyze complex, multi-dimensional datasets, this emerging field offers promising applications in improving diagnostic accuracy, predicting treatment responses, and forecasting disease progression, potentially transforming IBD patient care.
Method: The systematic review (SR) was conducted by searching the following databases: PubMed, PubMed PMC, BVS, Scopus, Web of Science, Embase, Cochrane, and ProQuest up to February 2024. Studies that employed AI in IBD applied to precision medicine were included.
Results: 139 studies on applying AI in precision medicine for IBD were identified. Most studies (>70%) were published after 2020, indicating a recent surge in interest. The AI applications primarily focused on diagnosis, treatment response prediction, and prognosis. Machine learning algorithms were predominantly used, particularly random forest, logistic regression, and support vector machines. Omics data were frequently employed as predictors, especially transcriptomics and microbiome analyses. Studies demonstrated good predictive performance across all three areas, with median AUC values ranging from 0.85 to 0.90.
Conclusion: AI applications in IBD show promising potential to enhance clinical practice, particularly in disease prognosis and predicting treatment response. However, clinical implementation requires further validation through prospective studies. Future research should focus on standardizing protocols, defining clinically significant outcomes, and evaluating the efficacy of these tools.